Previous close | 89.51 |
Open | 92.36 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 89.12 - 89.48 |
52-week range | 84.53 - 119.56 |
Volume | |
Avg. volume | 63,990 |
Market cap | N/A |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | 0.16 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The Food and Drug Administration has approved Winrevair, Merck's (MRK) latest drug to treat pulmonary arterial hypertension, a lung condition. Investors have been anxiously awaiting the approval as the company is set to lose its patent for Keytruda. The drug will help to reduce the risk of death and worsening events in patients by 84%. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to discuss how the treatment could offer a potential path to the upside for Merck. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's Note: This article was written by Gabriel Roy
Moderna (MRNA) shares are trading higher Monday after the biotechnology company revealed the start of a clinical trial for a skin cancer treatment. Moderna has partnered with the pharmaceutical giant Merck (MRK) to test the drug, in a bid to diversify beyond its core vaccine business. Yahoo Finance's Julie Hyman and Brian Sozzi breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Angel Smith
Moderna posted strong results despite investors assuming a loss for the year.